Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219110 · ClinicalTrials.gov registry record · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
A NA study of Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection and Hemolytic-Uremic Syndrome, sponsored by University of Calgary.
- Recruiting
- Registry status
- NA
- Development phase
- 1,040
- Enrollment target
- 20
- Study locations
NCT05219110 is a NA study of Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection and Hemolytic-Uremic Syndrome that is actively recruiting participants, run by University of Calgary. The registered enrollment target is 1,040 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05219110, a NA study of Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection and Hemolytic-Uremic Syndrome, is actively recruiting participants, sponsored by University of Calgary.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,040 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Conditions Studied
Interventions
- OTHER Infusion of 200% maintenance fluids as balanced crystalloid IV solution
- OTHER Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Study Locations (20)
Ohio
- Children's Hospital Medical Center - Cincinnati
- University Hospitals Rainbow Babies & Children's Hospital - Cleveland
- Nationwide Children's Hospital - Columbus
California
- University of California, San Diego - La Jolla
- University of California, Davis - Sacramento
Kentucky
- University of Kentucky - Lexington
- Norton Children's Hospital - Louisville
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- University of Colorado Denver - Denver
District of Columbia
- Children's Research Institute - Washington D.C.
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,040 participants |
| Start Date | 2022-09-29 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05219110
The ClinicalTrials.gov registry entry for NCT05219110 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,040 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Calgary, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection appearing as the primary indexed condition, and to 2 interventions - of which Infusion of 200% maintenance fluids as balanced crystalloid IV solution is the first listed.
NCT05219110 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Ohio, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05219110 about?
NCT05219110 is a clinical study titled "Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection". The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conse...
What is the current status of trial NCT05219110?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,040 participants. The study started on 2022-09-29. Estimated completion is 2027-08-31.
What conditions does trial NCT05219110 study?
This clinical trial studies the following conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome.
What interventions are being tested in trial NCT05219110?
The interventions under investigation include: Infusion of 200% maintenance fluids as balanced crystalloid IV solution (OTHER), Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution (OTHER).
Who is sponsoring clinical trial NCT05219110?
This trial is sponsored by University of Calgary, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05219110 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection
All registered trials for this condition
Hemolytic-Uremic Syndrome
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.